Progentos Therapeutics
PrivateLast Round
Series A
May 20, 2024
Total Funding Raised
$65M
Company Overview
Progentos Therapeutics is a biotechnology company developing first-in-class small molecule therapeutics designed to regenerate myelin and restore function for patients with multiple sclerosis and other demyelinating diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Progentos Therapeutics Comparables
Compare Progentos Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Convelo Therapeutics | 89% | |
| Pheno Therapeutics | 87% | |
| Rewind Therapeutics | 87% |
Progentos Therapeutics Funding Rounds
Historical fundraising activity
Progentos Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Dolby Family Ventures | Series A |
| Forbion | Series A |
| Mission BioCapital | Series A |
| Longwood Fund | Series A |
| Alta Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 20, 2024
$65M round led by Forbion.
Progentos Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Progentos Therapeutics's valuation, stock price, and market status.
Is Progentos Therapeutics a public or private company?
Progentos Therapeutics is a private company.
What is the current stock price of Progentos Therapeutics?
Progentos Therapeutics is a private company, so its shares have no public market price. Caplight tracks Progentos Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Progentos Therapeutics worth (valuation)?
Valuation information for Progentos Therapeutics is not publicly available.
Can I buy Progentos Therapeutics stock?
Progentos Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Progentos Therapeutics's last funding round?
Progentos Therapeutics's most recent funding round was Series A on May 20, 2024.
Who are the main investors in Progentos Therapeutics?
Key investors in Progentos Therapeutics include Forbion.
Will Progentos Therapeutics IPO soon?
No public IPO plans have been announced for Progentos Therapeutics.
How can I track Progentos Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Progentos Therapeutics's shares on secondary markets.